Feasibility and acceptability of the delivery of a group telehealth intervention for support persons of patients receiving buprenorphine for opioid use disorder

被引:0
|
作者
Ueland, Elizabeth [1 ]
Nameth, Katherine [1 ]
Manuel, Jennifer K. [2 ,3 ]
Osilla, Karen Chan [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 1070 Arastradero Rd, Palo Alto, CA 94304 USA
[2] San Francisco VA Hlth Care Syst, 4150 Clement St, San Francisco, CA 94121 USA
[3] Univ Calif San Francisco, Dept Psychiat & Behav Sci, 675 18th St, San Francisco, CA 94143 USA
关键词
Opioid use disorders; CRAFT; Family; Buprenorphine; COMMUNITY REINFORCEMENT; TELEMEDICINE; INDIVIDUALS; EFFICACY; FAMILIES; ALCOHOL; ACCESS; CRAFT; CARE;
D O I
10.1016/j.josat.2025.209628
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Opioid-related overdoses increased substantially during the COVID-19 pandemic, eliciting an urgent demand for accessible treatment for individuals with opioid use disorder (OUD) and those who support them (support persons). Support persons can improve treatment initiation and retention in their individuals with OUD. Additionally, support persons may have their own mental health needs related to their loved one's OUD. Unfortunately, few treatment options exist for support persons of individuals with an OUD. A support personfocused group telehealth intervention (referred to as eINSPIRE) that is accessible and feasible could help fill the treatment gap for support persons and bolster outcomes for individuals with OUD. Methods: The study interviewed patients receiving buprenorphine (n = 9), their support persons (n = 12), and clinic staff members (n = 6) about their perceptions on a group telehealth intervention designed for support persons. Patient and support person dyads were recruited from two community health clinics to participate in a qualitative interview and/or focus group. Using classic content analysis, we then analyzed this data to evaluate the feasibility, acceptability, and usability of a group telehealth intervention for support persons. Results: The eINSPIRE intervention was deemed generally acceptable, feasible, and usable. All support persons (n = 12) agreed that group telehealth was acceptable and those who completed an eINSPIRE demo session found it usable (IUS = 72.5). Patients indicated that eINSPIRE would be beneficial for support persons, and could provide services that are unattainable to them in their immediate community, but that groups sometimes lacked intimacy. Participants also found group telehealth to be more accessible than in-person alternatives and suggested how to improve the delivery of the intervention. Conclusions: Group telehealth may be a feasible and acceptable option for delivering an intervention to support persons and could reduce barriers to treatment that this population often experiences due to competing demands. However, due to sample size limitations, more participant perspectives and future research are needed.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies
    De Aquino, Joao P.
    Parida, Suprit
    Avila-Quintero, Victor J.
    Flores, Jose
    Compton, Peggy
    Hickey, Thomas
    Gomez, Oscar
    Sofuoglu, Mehmet
    DRUG AND ALCOHOL DEPENDENCE, 2021, 228
  • [22] CHARACTERIZATION OF OBJECTIVE AND SUBJECTIVE SLEEP IN PATIENTS RECEIVING BUPRENORPHINE MAINTENANCE THERAPY FOR OPIOID USE DISORDER
    Speed, T. J.
    Finan, P. H.
    Kowalczyk, W. J.
    Tyburski, M.
    Epstein, D. H.
    Preston, K. L.
    SLEEP, 2017, 40 : A421 - A422
  • [23] Using buprenorphine to treat patients with opioid use disorder
    Radi, Joshua K.
    Fogarty, Kieran J.
    Lagerwey, Mary D.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (10): : 30 - 35
  • [24] TRENDS IN USE AND COSTS OF PRESUMPTIVE AND CONFIRMATORY URINE DRUG TESTS FOR PATIENTS RECEIVING BUPRENORPHINE FOR OPIOID USE DISORDER
    Cruz, Ricardo
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 : S325 - S325
  • [25] Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
    Flam-Ross, Juliet M.
    Marsh, Elizabeth
    Weitz, Michelle
    Savinkina, Alexandra
    Schackman, Bruce R.
    Wang, Jianing
    Madushani, R. W. M. A.
    Morgan, Jake R.
    Barocas, Joshua A.
    Walley, Alexander Y.
    Chrysanthopoulou, Stavroula A.
    Linas, Benjamin P.
    Assoumou, Sabrina A.
    JAMA NETWORK OPEN, 2023, 6 (09) : E2329583
  • [26] Recovery capital among people receiving treatment for opioid use disorder with buprenorphine
    Anna Beth Parlier-Ahmad
    Mishka Terplan
    Dace S. Svikis
    Laura Ellis
    Caitlin E. Martin
    Harm Reduction Journal, 18
  • [27] Recovery capital among people receiving treatment for opioid use disorder with buprenorphine
    Parlier-Ahmad, Anna Beth
    Terplan, Mishka
    Svikis, Dace S.
    Ellis, Laura
    Martin, Caitlin E.
    HARM REDUCTION JOURNAL, 2021, 18 (01)
  • [28] Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients' Perceptions and Attitudes
    Young, Gary J.
    Hasan, Md Mahmudul
    Young, Leonard D.
    Noor-E-Alam, Md.
    SUBSTANCE USE & MISUSE, 2023, 58 (04) : 512 - 519
  • [29] ASSESSING THE IMPACT OF TELEHEALTH DELIVERY ON ADHERENCE TO MEDICATIONS FOR OPIOID USE DISORDER
    Wang, Y.
    Shi, L.
    Bogulski, C.
    Hayes, C.
    Bledsoe, A.
    Winston, K. D.
    Meggett, K.
    Eswaran, H.
    VALUE IN HEALTH, 2024, 27 (06) : S230 - S230
  • [30] Overcoming barriers to traditional care delivery and pharmacy challenges: a qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder
    Monico, Laura B.
    Eastlick, Megan
    Michero, Darcy
    Pielsticker, Peyton
    Glasner, Suzette
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2025, 20 (01)